Forge, Roche Enter Antibiotic Alliance

Forge Therapeutics and Roche have entered into a research collaboration and option agreement for FG-LpxC LUNG, a novel antibiotic for the treatment of serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa. The FG-LpxC LUNG program is being developed to treat hospital-based infections, including those cited on the CDC's most urgent threats list, which commonly occur in people with weakened immune systems and chronic lung diseases.